Prior to joining Catawba Research, Allan Shepard was Chief Scientific Officer and Co-Founder for Element Diagnostics, LLC, a start-up from Physicians Choice Laboratory Services, where he led research efforts developing a diagnostic assay for bladder cancer. Prior to this, he was founder of EyeOPx, LLC, a life sciences company focused on discovering novel topical ocular drugs for the treatment of glaucoma. Allan formed EyeOPx after working for over 14 years as Associate Director and Head of In Vitro Pharmacology for Novartis Institutes for Biomedical Research (NIBR; formerly Alcon Laboratories, Inc.) where he led teams of scientists in ophthalmology research from target discovery to the clinic. To date, Allan has co-authored 34 peer-reviewed scientific publications and is co-inventor on 23 patents (issued or pending). For all these reasons, we call him "The Professor".
Allan received his Ph.D. in molecular biology from Mayo Clinic and a bachelor's degree in biochemistry from the University of Iowa.